Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Forest in
the ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark Forest' s performance against key rivals in the ethical
pharmaceutical sector
- See how the company will achieve strong growth up until 2011, when
Lexapro' s patent expiry will trigger a sharp decline in ethical sales
View Cart
